StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)
September 4, 2024 7:44 AM
Goldman Sachs analyst Chris Shibutani reiterated a Buy rating and $51.00 price target on Royalty Pharma (NASDAQ: RPRX).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
September 5, 2024 6:54 AM
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 3, 2024 5:14 PM
Ascendis Pharma (ASND) and Royalty Pharma (RPRX) Enter $150M Royalty Funding Agreement
September 3, 2024 5:07 PM
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
September 3, 2024 5:06 PM
